Annals of Internal Medicine · 1983 · 378 citations · 17 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyHematologic OncologyChemotherapy In Hematologic MalignanciesChemotherapy Toxicity ManagementCombination ChemotherapyHematologic Malignancy TherapyToxicity ManagementChemotherapy Dose-limiting ToxicityClinical RemissionLymphoma ChemotherapyLymphoma RelapseLymphoma Treatment ResponseRelapsed Diffuse Large B-cell LymphomaTumor Response EvaluationTumor Response Prediction
Prior regimens yielded a 46 % complete remission rate and 38 % 4‑year survival, with relapse‑free survival beyond 2 years considered curative. The study aimed to improve complete remission and survival rates in untreated advanced diffuse aggressive lymphoma patients. The regimen alternated flexible cycles of ProMACE and MOPP, with phase lengths guided by tumor response and a final ProMACE intensification. The alternating ProMACE‑MOPP protocol achieved 74 % complete remission, 65 % 4‑year survival, and an 18 % relapse rate among responders, with myelosuppression as the main toxicity and 10 % sepsis deaths, markedly improving outcomes over prior regimens.
A new treatment program was developed in an attempt to increase the complete remission rate and survival of previously untreated patients with advanced stages of diffuse aggressive lymphomas. A flexible number of cycles of ProMACE chemotherapy (prednisone, methotrexate, doxorubicin, cyclophosphamide, and epipodophyllotoxin VP-16) was alternated with a flexible number of cycles of MOPP chemotherapy (mechlorethamine, vincristine sulfate, procarbazine, and prednisone), and finally late intensification with ProMACE therapy was given. The duration of each phase of treatment was determined by the patient's rate of tumor response. Complete remissions were achieved in 55 of 74 patients (74%) with a median duration of follow-up exceeding 2 1/2 years. Only ten of the complete responders (18%) have had relapse. The dose-limiting toxicity is myelosuppression, and eight patients (10%) died from sepsis. Median survival for all patients has not been reached but is predicted to exceed 4 years with 65% of patients alive at 4 years. Previously we achieved a 46% complete remission rate with 38% of all patients alive at 4 years; relapse-free survival beyond 2 years was tantamount to cure. Therefore, ProMACE-MOPP chemotherapy represents a substantial improvement in treating patients with diffuse aggressive lymphomas.
17
Report of the Committee on Hodgkin's Disease Staging Classification.
Paul P. Carbone, Henry S. Kaplan, K. Musshoff et al. · PubMed · 1971 · 4.2K citations
ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE
V. T. DeVita, G. P. Canellos, Bruce A. Chabner et al. · The Lancet · 1975 · 485 citations
Curability of Advanced Hodgkin's Disease with Chemotherapy
Vincent T. DeVita · Annals of Internal Medicine · 1980 · 474 citations
Medicine, Oncology, Pharmacotherapy +15